Tryp Therapeutics Inc (TRYPF) Corporate Presentation

Corporate Presentation Fall 2021 LEADING THE NEXT WAVE OF PSYCHEDELIC DRUG DEVELOPMENT Tryp’s differentiated approach to psychedelic drug development has the potential to deliver urgently needed treatments to millions of patients suffering from chronic pain and other diseases while creating significant opportunity for investors. 35 1. Unique, highly valuable indications Our imminent Phase 2a clinical trials represent the first time that any type of psychedelic has been evaluated for the respective indications in a Phase 2 study. Fibromyalgia, phantom limb pain, CRPS, binge eating disorder, and hypothalamic obesity represent more than $12 billion of potential peak annual sales upon successful commercialization. We are well positioned for success: